0001209191-20-052337.txt : 20200929 0001209191-20-052337.hdr.sgml : 20200929 20200929163827 ACCESSION NUMBER: 0001209191-20-052337 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200925 FILED AS OF DATE: 20200929 DATE AS OF CHANGE: 20200929 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Thompson Peter A. CENTRAL INDEX KEY: 0001357522 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39539 FILM NUMBER: 201209312 MAIL ADDRESS: STREET 1: C/O ANTHERA PHARMACEUTICALS, INC. STREET 2: 25801 INDUSTRIAL BOULEVARD, SUITE B CITY: HAYWARD STATE: CA ZIP: 94545 FORMER NAME: FORMER CONFORMED NAME: Thompson Peter A DATE OF NAME CHANGE: 20060327 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PMV Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001699382 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463218129 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8 CLARKE DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: (609) 642-6664 MAIL ADDRESS: STREET 1: 8 CLARKE DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-09-25 0 0001699382 PMV Pharmaceuticals, Inc. PMVP 0001357522 Thompson Peter A. C/O PMV PHARMACEUTICALS, INC. 8 CLARKE DRIVE, SUITE 3 CRANBURY NJ 08512 1 0 1 0 Common Stock 2020-09-25 4 P 0 475000 18.00 A 475000 I See footnote Common Stock 2020-09-29 4 C 0 4025076 A 4500076 I See footnote Common Stock 2020-09-29 4 C 0 1076891 A 5576967 I See footnote Common Stock 2020-09-29 4 C 0 518191 A 6095158 I See footnote Common Stock 2020-09-29 4 C 0 380133 A 6475291 I See footnote Common Stock 2020-09-29 4 C 0 114039 A 114039 I See footnote Common Stock 2020-09-25 4 P 0 475000 18.00 A 475000 I See footnote Series A Preferred Stock 2020-09-29 4 C 0 4025076 0.00 D Common Stock 4025076 0 I See footnote Series B Preferred Stock 2020-09-29 4 C 0 1076891 0.00 D Common Stock 1076891 0 I See footnote Series C Preferred Stock 2020-09-29 4 C 0 518191 0.00 D Common Stock 518191 0 I See footnote Series D Preferred Stock 2020-09-29 4 C 0 380133 0.00 D Common Stock 380133 0 I See footnote Series D Preferred Stock 2020-09-29 4 C 0 114039 0.00 D Common Stock 114039 0 I See footnote The shares are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI V. Each of GP V, OrbiMed Advisors, OrbiMed Genesis GP LLC ("Genesis GP"), OrbiMed Capital LLC ("OrbiMed Capital"), Messrs. Borho and Silverstein, Dr. Gordon, and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Person is an employee of OrbiMed Advisors. The shares of each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. The shares are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). Genesis GP is the general partner of Genesis Master Fund and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis Master Fund and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund. The shares are held of record by OrbiMed Partners Master Fund Limited ("OPM"). OrbiMed Capital is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of the Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPM. /s/ David H. Mack, attorney-in-fact 2020-09-29